Eli Lilly And Company

This study tested an experimental drug called peresolimab in adults with moderate-to-severe rheumatoid arthritis whose current treatments weren't working well enough. Nearly 500 participants received either peresolimab or a placebo to see if the drug could safely reduce joint pai…

This was an early-stage study to test the safety and find the right dose of an experimental drug called LY3405105 for people with advanced solid tumors. The trial enrolled 54 participants with various advanced cancers to see if the drug was safe and if it showed any signs of shri…

This early-stage study aimed to check the safety of an experimental drug called LY3872386 for treating atopic dermatitis (eczema). It involved a small group of healthy volunteers and people with eczema to see how their bodies handled the drug. The study was terminated early, so n…

This study aimed to find the right dose and check the safety of the drug baricitinib for children aged 1 to 18 who were hospitalized with COVID-19. It was designed to see if the drug could help control the disease and prevent kids from needing more serious breathing support. The …

This study tested whether an experimental drug called LY3540378 could help adults with a specific type of worsening heart failure where the heart pumps normally but doesn't relax properly. The trial enrolled 332 participants who had recently been hospitalized or needed urgent tre…

This study tested an experimental drug called LY3454738 to see if it could reduce the severity of moderate-to-severe eczema (atopic dermatitis) in adults. It was a Phase 2 trial involving 234 participants who were compared against a placebo group over 52 weeks. The main goal was …

This early-stage study tested the safety of a new drug called LY3127804, both alone and combined with an existing cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find safe dosage levels and understand how the body processes these drugs. Th…

This study tested whether a medication called lasmiditan could safely and effectively relieve migraine pain in children and teenagers aged 6 to 17. Researchers compared different doses of the drug against a placebo (inactive pill) in 851 young participants over about 20 weeks. Th…

This study aimed to evaluate the long-term safety and effectiveness of lasmiditan for treating migraine attacks in children aged 6 to 17. The 12-month trial followed 566 young participants who had previously completed related studies, focusing on side effects and migraine relief.…

This early study aimed to understand the safety and how the body processes the experimental drug LY3526318 when taken by mouth. It involved 76 healthy volunteers who received either single or multiple doses over several weeks. The study was terminated and focused on measuring sid…

This early-stage study aimed to check the safety and side effects of a new drug called LY3463251 when given as an injection under the skin. It involved 118 healthy and overweight volunteers to see how their bodies handled single and multiple doses. The main goal was to gather bas…